Clinical trial
Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory…
NCT00276679 · Children's Cancer and Leukaemia Group, Other · Completed
Key facts
| NCT number | NCT00276679 |
|---|---|
| Title | Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma |
| Official title | Phase II Study of Temozolomide (Temodal) in Children Over 1 Year of Age With Relapsed or Refractory High Risk Neuroblastoma |
| Lead sponsor | Children's Cancer and Leukaemia Group, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroblastoma |
| Intervention type | Drug |
| Interventions | temozolomide |
| Start date | Apr 1, 2003 |
| Completion | Nov 1, 2006 |
| First posted | Jan 13, 2006 |
| Last update posted | Sep 17, 2013 |
| Countries | France, Ireland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: